Aastrom Biosciences, Inc. (Aastrom) is a development stage company. The Company is focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. The Company is engaged in developing patient-specific, expanded multicellular therapies for uses in the treatment of severe, chronic ischemic cardiovascular diseases. The Company's cell-manufacturing technology enables the manufacture of multicellular therapies, expanded from an adult's own bone marrow and delivered directly to damage tissues. The Company's therapy is produced at the Company's cell manufacturing facility in the United States. During the year ended December 31, 2011, nearly 200 patients had been treated in clinical trials using ixmyelocel-T (as of December 31, 2011, over 400 patients treated). In March 2013, it announced strategic change in research and development programs to focus on the clinical development of lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM).